Psyched Wellness to Present at the Psychedelic Investment Series on Monday, May 31, 2021
Toronto, Ontario – May 11, 2021 – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the company will be participating in the upcoming Psychedelic Capital virtual event.
Psyched will be presenting at the next edition of the psychedelic investment series on Monday, May 31, 2021 at 1:30 PM EST.
The Psychedelic Capital Investment Conference is dedicated to providing investment grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe.
Each month, the #PsyCap features the top companies, latest IPOs, newest opportunities, and deepest insights into the emerging psychedelic space. Investment thought leaders and wealth influencers provide our audiences with valuable insights. C-suite company executives covering every corner of the psychedelics industries, media and financial services companies are available to speak one on one. This is a must-attend for investors.
For more information and/or to register for the conference please visit: https://microdose.buzz/psycap
“I look forward to participating in this event with my director, Terry Booth. PsyCap has done a great job attracting top companies in the sector and we appreciate the opportunity to introduce Psyched Wellness to their investing audience.” says Jeffrey Stevens, CEO of the Company.
For further information, please contact:
Chief Executive Officer
Psyched Wellness Ltd.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Note Regarding Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to receiving the Initial Supply on the timelines and in quantities mentioned above, the quality and potency of the Amanita muscaria mushrooms received from MB MEMEL GOODS, the intended use of the Initial Supply and the Company’s ability to reach commercial production. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended, including MB MEMEL GOODS being unable to deliver Initial Supply on the timelines and in quantities mentioned above, the quality and potency of the Amanita muscaria mushrooms received from MB MEMEL GOODS being unfit for AME-1, and the inability of the Company to reach commercial production. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
Please confirm your consent to receive electronic communications from by entering your email address and clicking the sign up button.